Regeneron

Regeneron is a biotechnology company that develops and commercializes medicines for the treatment of metabolic, inflammatory and infectious diseases. Read more

694 Followers on Owler
694 Followers on Owler
694 Followers on Owler
694 Followers on Owler

Regeneron

Regeneron is a biotechnology company that develops and commercializes medicines for the treatment of metabolic, inflammatory and infectious diseases. Read more

Leonard S Schleifer's photo - President & CEO of Regeneron

President & CEO

Leonard S Schleifer

CEO Approval Rating

94/100

Founded:

1988

Status:

PublicIndependent CompanyNASDAQREGN

REGENERON TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Novartis has been one of Regeneron's top competitors. Novartis is a Public company that was founded in 1996 in Basel, Basel-City. Like Regeneron, Novartis also competes in the Pharmaceuticals sector. Compared to Regeneron, Novartis has 102,600 more employees.

Roche is seen as one of Regeneron's biggest rivals. Roche is a Public company that was founded in Basel, Basel-Country in 1896. Like Regeneron, Roche also operates in the Pharmaceuticals sector. Roche has 92,600 more employees vs. Regeneron.

Allergan is perceived as one of Regeneron's biggest rivals. Allergan was founded in Coolock, County Dublin} in 1948. Allergan operates in the Health Care Supplies industry. Compared to Regeneron, Allergan generates $7.5B more revenue.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Takeda a competitor of Regeneron?

Regeneron Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$8.5B

Regeneron's revenue is the ranked 17th among it's top 10 competitors. The top 10 competitors average 26.7B. Over the last four quarters, Regeneron's revenue has grown by 29.5%. Specifically, in Q1 2021's revenue was $2.5B; in Q4 2020, it was $2.4B; in Q3 2020, it was $2.3B; in Q2 2020, Regeneron's revenue was $2B.

Regeneron Acquisitions

No recent acquisitions found related to Regeneron

Regeneron Funding History

Since Regeneron was founded in 1988, it has participated in 2 rounds of funding. In total Regeneron has raised $2.1B. Regeneron's last funding round was on Aug 2020 for a total of $2.0B

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Debt
Aug 2020
$2B
-
IPO
Jan 1991
$91.4M
-

Since Regeneron was founded in 1988, it has participated in 2 rounds of funding. In total Regeneron has raised $2.1B. Regeneron's last funding round was on Aug 2020 for a total of $2.0B

Regeneron Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

DNAnexus provides cloud-based genome informatics and data management solutions for the healthcare sector.
$100M
Jun 08, 2020
Series G
-
Vyriad is a biotechnology company that develops novel oncolytic therapies for the treatment of cancer.
$24.4M
Oct 29, 2019
Series B
-
Decibel Therapeutics is a biotechnology company that develops and commercializes drugs for the treatment of ear, nose and throat diseases.
$55M
Jun 18, 2018
Series C
Feb 11, 2021

Regeneron News

May 6, 2021MarketWatch

Regeneron stock rises, as profit, revenue and sales of SARS-CoV-2 antibody cocktail beat expectations

Shares of Regeneron Pharmaceuticals Inc. rose 0.8% in premarket trading Thursday, after the biotechno... See more »
May 6, 2021MarketScreener

Regeneron's COVID-19 therapy helps boost quarterly profit

(marketscreener.com) -Regeneron Pharmaceuticals Inc reported a quarterly profit on Thursday that beat... See more »
April 26, 2021FiercePharma

Regeneron CEO Schleifer bags massive $135M payday after 2020 pandemic wins

Regeneron CEO Schleifer bags massive $135M payday after 2020 pandemic wins fkansteiner Mon, 04/26/202... See more »
April 23, 2021FiercePharma

report

Regeneron looks to inject another $330M into long-running manufacturing expansion plan: report fkanst... See more »
April 22, 2021Seeking Alpha

Close To Regenerated Again

April 21, 2021MarketScreener

Roche's first-quarter COVID-19 tests business saves the day for slumping drug division

(marketscreener.com)https://www.marketscreener.com/quote/stock/REGENERON-PHARMACEUTICALS-10649/news/R... See more »
April 17, 2021Latest Talks

Regeneron Antibody Cocktail Offers COVID Protection

April 13, 2021 - People living with someone who has COVID-19 appear to get powerful protection agains... See more »

Regeneron Press Releases

February 1, 2021PR Newswire

New Dupixent (dupilumab) Data Showcasing Improvements Across Four Type 2 Inflammatory Diseases to be Presented at 2021 AAAAI Annual Meeting

TARRYTOWN, N.Y. and PARIS, Feb. 1, 2021 /PRNewswire/ -- Improvements were noted across key disease me... See more »
November 16, 2020Newswise

UCLA Health and Regeneron Genetics Center enter research collaboration to provide whole exome sequencing for UCLA patients

UCLA Health has entered into a collaborative research agreement with the Regeneron Genetics Center (R... See more »
October 6, 2020StreetInsider

Allele Biotechnology and Pharmaceuticals Files Two Lawsuits for Patent Infringement for the Unauthorized Use of mNeonGreen in Development and Testing of COVID Vaccines and Therapeutics

New York Lawsuit Filed Against Regeneron Pharmaceuticals, Inc. California Lawsuit Filed Against Pfize... See more »
July 7, 2020PR Newswire

Regeneron Utilizes Icertis Contract Management Platform for Contracting System Transformation

BELLEVUE, Wash., July 7, 2020 /PRNewswire/ -- Icertis, the leading provider of enterprise contract ma... See more »
June 17, 2020StreetInsider

ISA Pharmaceuticals Strengthens Strategic Immuno-Oncology Collaboration With Regeneron

LEIDEN, The Netherlands, June 17, 2020 /PRNewswire/ -- ISA Pharmaceuticals B.V., a private clinical-s... See more »
June 3, 2020GlobeNewswire

Kymab announces that the US Patent Trial and Appeal Board rejects a fifth request by Regeneron for invalidation of Kymab's US patents

Kymab announces that the US Patent Trial and Appeal Board rejects a fifthrequest by Regeneron for inv... See more »
March 30, 2020StreetInsider

Regeneron Announces American College of Cardiology Presentation of Positive Phase 3 Evinacumab Results in Patients with Severe Inherited Form of High Cholesterol

TARRYTOWN, N.Y., March 30, 2020 /PRNewswire/ --Â Results from separate positive Phase 3 trial of Pral... See more »

Regeneron Videos

September 23, 2020Regeneron Youtube Channel

"Regeneron's Mission: Our Snapshot" on YOUTUBE

January 3, 2020Regeneron Youtube Channel

"Creating our Medicines with Zack" on YOUTUBE

December 21, 2019Regeneron Youtube Channel

"Vishal Always Asks the "Why" Questions" on YOUTUBE

December 19, 2019Regeneron Youtube Channel

"Outsmarting Cancer with Petra" on YOUTUBE

Social Media

Regeneron Headquarters

777 Old Saw Mill River Road

Tarrytown, New York10591

1-914-847-7000

Driving Directions »

Trending Companies

Regeneron Summary

ABOUT

Overview

Regeneron is a biotechnology company that develops and commercializes medicines for the treatment of metabolic, inflammatory and infectious diseases. Regeneron was founded in 1988. Regeneron's headquarters is located in Tarrytown, New York, USA 10591....

CEO

Regeneron's President & CEO, Leonard S Schleifer, currently has an approval rating of 94%. Regeneron's primary competitors are Novartis, Roche & Allergan.

Website

regeneron.com

Frequently Asked Questions about Regeneron

  1. When was Regeneron founded?

    Regeneron was founded in 1988
  2. Who is Regeneron's CEO?

    Regeneron's CEO is Leonard S Schleifer
  3. How much revenue does Regeneron generate?

    Regeneron generates $8.5B in revenue
  4. How much funding does Regeneron have?

    Regeneron has historically raised $2.1B in funding
  5. Where is Regeneron's headquarters?

    Regeneron's headquarters is in Tarrytown New York, USA
  1. How many employees does Regeneron have?

    Regeneron has 7,400 employees
  2. What sector does Regeneron operate in?

    Regeneron is in Pharmaceuticals, Biotechnology
  3. Who are Regeneron's competitors?

    Regeneron's top competitors are Novartis, Roche, Allergan
  4. Who has Regeneron invested in?

    Regeneron's has invested in companies such as DNAnexus, Vyriad, Decibel